aveo pharmaceuticals inc (AVEO) Key Developments
AVEO Pharmaceuticals, Inc.(NasdaqGS:AVEO) dropped from Russell 2000 Index
Jun 30 14
AVEO Pharmaceuticals, Inc. will be removed from the Russell 2000 Index.
AVEO Pharmaceuticals, Inc.(NasdaqGS:AVEO) dropped from Russell 3000 Index
Jun 30 14
AVEO Pharmaceuticals, Inc. will be removed from the Russell 3000 Index.
AVEO Pharmaceuticals, Inc. Announces Executive Changes
Jun 23 14
On June 19, 2014, the Board of Directors of AVEO Pharmaceuticals, Inc. promoted Matthew Dallas to the position of Vice President, Finance and appointed Mr. Dallas Treasurer as acting principal accounting officer of the company effective as of July 1, 2014. Mr. Dallas, 39, currently has responsibility for the company's Finance, IT, and Facilities functions. He previously served as AVEO's Senior Director of Finance and Director of Financial Planning and Analysis.
AVEO Oncology Announces AV-203 Phase 1 Results
May 31 14
AVEO Oncology announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO's ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. A total of 22 patients were evaluated in the Phase 1, open-label, dose-escalation study. Objectives included safety, tolerability, dose limiting toxicities (DLT), maximum tolerated dose and/or recommended phase 2 dose in patients with advanced solid tumors. Evaluation of NRG-1 as a predictive biomarker was an exploratory objective. Patients received 2, 5, 9, 14, or 20 mg/kg of AV-203 intravenously once every 2 weeks (2 times per 28 day cycle). AV-203 was found to be generally safe and well-tolerated, with diarrhea and decreased appetite as the most common treatment-emergent and treatment-related adverse events (all grade). Across all doses of AV-203, there was a single DLT that occurred in an elderly patient at the lowest dose cohort (inability to tolerate study drug). The recommended Phase 2 dose was established at 20mg/kg intravenously every 2 weeks. No anti-drug antibodies were detected, and pharmacokinetic results indicated a dose-proportional increase in levels of AV-203. Among 22 evaluable patients, stable disease was the best response for 8 patients, including a partial response lasting 6 cycles and a long-term stable disease lasting at least 22 cycles (>98 weeks), resulting in a disease control rate of 36%. Neuregulin-1 (NRG-1, also known as heregulin or HRG) status, which AVEO's preclinical studies suggest is predictive of AV-203 anti-tumor activity, was analyzed via RT-PCR. Of 14 subjects analyzed for NRG-1 expression, two patients were NRG-1 positive, one of whom, a patient with squamous non--small cell lung cancer, achieved a partial response. CLIA (Clinical Laboratory Improvements Amendment) validation is complete for an NRG-1 biomarker assay for potential use in patient selection in future clinical trials. AV-203 is a potent and selective ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers. Preclinical data also suggest that Neuregulin-1 (NRG-1) levels predict AV-203 anti-tumor activity. NRG-1, also known as heregulin (HRG), is the only known ligand of ErbB3, and the most potent activator of the ErbB3/HER2 complex.
AVEO Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 08:30 AM
May 7 14
AVEO Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 08:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Tuan Ha-Ngoc, Chief Executive Officer, President, Acting Chief Financial Officer, Principal Accounting Officer and Director.